2020 Advanced Patients and Their Families Conference: Clinical Trials in Vasculitis: What's New, What's for You

Introducing Dr. Peter Merkel.	1:47
Types of Clinical Research Studies.	3:41
What’s really new in AAV?	7:12
PEXIVAS. Plasma Exchange and Glucocorticoids in Severe ANCA-Associated Vasculitis	7:23
The ADVOCATE Trial: (Avacopan).	9:06
Mepolizumab or Placebo for EGPA.	11:12
VCRB Longitudinal Study of EGPA 2019.	12:21
DADA2: PAN-Like Disease.	12:36
Trial of Tocilizumab in Giant Cell Arteritis.	14:11
Treatment of Vasculitis: Unmet needs.	16:24
Genetics / Genomics.	18:39
Metabolics / Microbiome Research.	19:26
Vasculitis COVID-19 Project.	21:24
V-PREG: Vasculitis Pregnancy Registry.	23:15
Why should you participate in clinical research in vasculitis?	23:55
Q&A: When do you anticipate that Avocopan could get FDA approval?	27:18
Q&A: Can you comment on the long-term safety of Rituximab?	29:00
Q&A: Can you comment on COVID-19 vaccines and patients with vasculitis?	30:22

Dr. Peter Merkel delivers a high-level overview of the types of clinical research studies into vasculitis. He covers such studies as PEXIVAS, ADVOCATE (Avacopan), and Tocilizumab in Giant Cell Artertis. Moreover, Dr. Merkel discusses some of the unmet and needs and challenges facing researchers. Finally, he talks about why vasculitis research is dependent on the participation of patients.

Peter A. Merkel, MD
Professor of Medicine and Epidemiology
Chief, Division of Rheumatology
University of Pennsylvania

Resources

Be Inspired

Educational Videos